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INTRODUCTION
Platinum-based chemotherapy has been the standard of care for patients with muscle invasive and metastatic urothelial carcinoma for over 20 years(1-3), and neoadjuvant cisplatin-based chemotherapy leads to a 14-25% relative risk reduction for death from muscle invasive urothelial carcinoma (cT2-T4aN0M0) (3) (4) (5) . Pathologic downstaging to complete response (pT0) or carcinoma in situ (pTis) at cystectomy occurs in 26-38% of patients treated with neoadjuvant chemotherapy compared to 12.3-15% for patients undergoing cystectomy alone (3, 4, 6) , and the 5-year survival for pT0/pTis patients is 85% after neoadjuvant chemotherapy(3) compared to 43% for patients with persistent muscle invasive disease ( pT2) (7) . Therefore, the benefit of neoadjuvant chemotherapy appears to be most dramatic in patients who are found to have pathological complete responses at the time of surgical resection. However, the inability to predict which patients will derive clinical benefit has limited the use of this toxic approach in the urologic community (8) (9) (10) .
Cisplatin causes accumulation of DNA crosslinks, which interfere with DNA replication and gene transcription, and eventually promote cell death. Repair of cisplatin-induced DNA damage occurs primarily through DNA repair pathways such as nucleotide excision repair (NER) (11) and homologous recombination (which includes BRCA1 and BRCA2). (12) . The NER pathway involves multiple genes, including ERCC1-5, CDK7, DDB1-2, XPA, and XPC. (13) Germline alterations in NER genes result in multiple recessive inherited disorders, including xeroderma pigmentosum (XP) (13) . Due to a deficiency in NER, XP patients have significantly increased risk of developing skin cancers and other malignancies (14) .
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Author Manuscript Published OnlineFirst on August 5, 2014; DOI: 10.1158/2159-8290.CD- Germline or expression-based changes in several NER genes have been suggested to modulate clinical response to cisplatin-based chemotherapy (15, 16) . However, prospective studies have not confirmed these observations (17, 18) . ERCC2 (an NER helicase) loss-of-function correlates with cisplatin sensitivity in preclinical models (19) , while ERCC2 overexpression leads to cisplatin resistance (20) . These data suggest that tumors with loss of NER function may exhibit increased cisplatin sensitivity, and recent data has identified somatic ERCC2 mutations in 7-12% of urothelial carcinomas(21, 22).
We hypothesized that somatic mutations in the NER pathway may correlate with response to cisplatin-based neoadjuvant chemotherapy in urothelial carcinoma patients.
To test this, and more generally to define genomic correlates of chemotherapy response, we performed whole exome sequencing of urothelial carcinoma tumors from patients with extreme responses to neoadjuvant cisplatin-based combination chemotherapy.
RESULTS

Somatic genetic alterations in muscle invasive urothelial carcinoma
We sequenced pre-treatment tumor and germline DNA from 50 patients treated with neoadjuvant cisplatin-based chemotherapy for muscle invasive urothelial carcinoma; 25 "responders" had no residual invasive disease (pT0/pTis) on pathologic examination following cystectomy, and 25 "non-responders" had residual muscle-invasive ( pT2) disease (Fig. 1A, Methods) . Although multiple chemotherapeutic regimens were 6 The mean target coverage from whole exome sequencing (WES) was 121X for tumors and 130X for paired germline samples (Supplementary Table 1 ). The median mutation rate was 9.7 mutations per megabase (mutations/Mb) for responders and 4.4 mutations/Mb for non-responders (P = 0.0003; Mann-Whitney test) (Fig. 1B, S1A- A statistical assessment(23) of the base mutations and short insertion/deletions across both responders and non-responders nominated four significantly altered genes previously implicated in urothelial carcinoma (21, 22, 24) : TP53, RB1, KDM6A, and ARID1A (Fig. 1B, Supplementary Table 3-4) . In addition, nine non-synonymous somatic mutations were observed in ERCC2 (Fig. 1B, S2 ; Supplementary Table 2) .
Although ERCC2 did not reach cohort-wide statistical significance, its known role in DNA repair and report of being recurrently mutated in bladder cancer(21, 22) raised the possibility that ERCC2 mutations might associate with cisplatin response.
Somatic ERCC2 mutations in cisplatin-based chemotherapy responders
We performed an enrichment analysis to identify genes that were selectively mutated in the responders compared to non-responders (Online Methods). Among 3,277 genes with at least one possibly damaging somatic alteration (Online Methods), ERCC2 was the only gene significantly enriched in the responder cohort ( Fig. 2A, Supplementary Tables 5-6). Indeed, all ERCC2 non-synonymous somatic mutations occurred in the cisplatin sensitive tumors (P < 0.001; Fisher's exact test). ERCC2 remained significantly enriched in responders following false discovery analysis performed on genes in which the mutation frequency afforded adequate power (q = 0.007; Benjamini-Hochberg) ( 2B). Moreover, the enrichment for ERCC2 mutations in the responder group was significant when adjusted for differences in overall mutation rate between responders and non-responders (P = 0.04; binomial test). Towards this end, the median background mutation rate for ERCC2 mutant tumors (15.5 mutations per megabase) was significantly elevated compared to ERCC2 wild-type tumors (5.1 mutations per megabase) (P = 0.01; Mann-Whitney test) (Supplementary Fig. 1B) , consistent with a possible DNA repair defect and prior reports (22) .
The somatic ERCC2 mutation frequency in the responder cohort was also compared to two unselected bladder cancer populations: 130 cases from the Cancer Genome Atlas (TCGA)(21) and 99 cases from a Chinese patient cohort (22) (Fig. 2C) . When compared to these unselected populations, ERCC2 mutations were significantly enriched in the cisplatin responder cohort (36% of cases; P < 0.001; binomial test) (Fig. 2C) . ERCC2 mutation status does not appear to be prognostic, as it had no impact on overall survival in the TCGA cohort (P = 0.77; Log-Rank) (Supplementary Fig. 3 ). To determine the relative abundance of somatic ERCC2 mutations in other tumor types, TCGA data from 19 tumor types (n = 4,429) was queried (25) . Somatic ERCC2 mutations were observed at low frequencies (< 4%) in 11 other tumor types (Fig. 3A-B) .
All identified somatic ERCC2 mutations occurred at highly conserved amino acid positions within or immediately adjacent to the helicase domains (Fig. 3A, C, S4) .
Similarly, germline ERCC2 mutations in patients with XP (complementation group D) and XP with combined Cockayne syndrome (XP/CS), two disorders characterized by NER function, cluster within helicase domains (Fig. 3C) . Conversely, mutations causing trichothiodystrophy, a disease resulting from alteration of ERCC2's role in transcription, are distributed throughout the protein (26) . Fig. 4A ). Expression of wild-type (WT) ERCC2 rescued cisplatin sensitivity of the ERCC2-deficient cell line, whereas none of the ERCC2 mutants rescued cisplatin sensitivity (Fig. 4B) . The IC 50 for the ERCC2 WT -complemented cell line was significantly higher than the ERCC2-deficient parent cell line (P < 0.0001; ANOVA), whereas the IC 50 for each ERCC2-mutant complemented cell line was not significantly different than the parent ERCC2-deficient parent cell line (Fig 4C) . Similarly, the IC 50 for the ERCC2 WT cell line was significantly higher than the ERCC2-deficient and mutant cell lines (P < 0.0001; ANOVA).
The NER pathway repairs DNA lesions other than cisplatin adducts, so we also tested the effect of the identified ERCC2 mutations on NER-mediated repair of UV-induced DNA damage. WT and mutant ERCC2 complemented cell lines were exposed to increasing doses of UV irradiation, and clonogenic survival was measured ( Fig. 5A-C) .
Whereas the ERCC2
WT -complemented cell line rescued UV sensitivity, the UV sensitivities of the ERCC2-mutant complemented cell lines were not significantly different than that of the ERCC2-deficient parent cell line. Taken together, these experiments suggest that the observed ERCC2 mutations result in loss of normal NER capacity.
Since the overall mutation rate was higher in ERCC2-mutated tumors, we hypothesized that ERCC2 mutations may be broadly contributing to genomic instability. Thus, we
Research. (Fig 6A-D) . However, following cisplatin exposure, significantly fewer chromosomal aberrations were observed in the ERCC2 WT -complemented cell line compared to the ERCC2-deficient parent cell line (P = 0.03; ANOVA), whereas expression of the ERCC2 mutants resulted in no rescue of chromosomal stability (P > 0.5) (Fig. 6D) . These data suggest that the responderassociated ERCC2 mutations may contribute to overall genomic instability in these tumors. Table S2 ).
Other DNA repair gene alterations
There were no nonsynonymous BRCA1 or BRCA2 mutations in the non-responders (Supplementary Table S2 ). These results are consistent with the known sensitivity of BRCA-mutant tumors (e.g. BRCA1/2-mutant breast or ovarian cancer) to platinumcontaining regimens (27) . While somatic ERCC2 mutations were the only DNA repair gene mutations enriched in the responders, singleton missense mutations of uncertain significance were observed in DNA damage response genes in both responders and non-responders, and are of unknown functional relevance. 
DISCUSSION
In bladder cancer, the clinical benefit of neoadjuvant chemotherapy is most apparent when pathological downstaging to pT0 or pTis is achieved at surgical resection following cisplatin-based chemotherapy. However, the lack of a predictive biomarker for clinical benefit from neoadjuvant cisplatin-based chemotherapy has limited the use of this approach in the clinical community due to toxicity concerns. Using an extreme phenotype analysis, we have identified an association between somatic ERCC2 mutations and pathologic complete response to neoadjuvant cisplatin-based chemotherapy in muscle invasive urothelial carcinoma. While ERCC2 mutations occur in approximately 12% of unselected cases, 36% of cisplatin-based chemotherapy responders in our cohort harbored somatic ERCC2 non-synonymous mutations.
Moreover, all ERCC2 mutant tumors responded to neoadjuvant chemotherapy.
The NER pathway is a highly conserved DNA repair system that identifies and repairs bulky DNA adducts arising from genotoxic agents such as cisplatin. The NER helicase ERCC2 unwinds duplex DNA near the damage site through the coordinated action of two conserved helicase domains. All ERCC2 mutations identified in this study occurred at conserved positions within or adjacent to these helicase domains, and the identified mutants all failed to complement cisplatin or UV sensitivity of an ERCC2-deficient cell line. Together, these data suggest that the mutations result in loss of normal ERCC2 function, leading to increased tumor cell sensitivity to DNA-damaging agents such as cisplatin.
Interestingly, in seven (78%) of the ERCC2-mutant cases, the ERCC2 mutation allelic fraction was < 0.5 (Supplementary Table S2 ), suggesting that WT ERCC2 remains present at one allele. Therefore, the cisplatin sensitivity phenotype may result from a haploinsufficient or dominant negative effect of a heterozygous ERCC2 mutation, rather Despite providing a potential growth advantage, mutation of one ERCC2 allele may render tumor cells susceptible to DNA damaging agent such as cisplatin if inadequate levels of WT ERCC2 are present to support NER (i.e. haploinsufficiency). Alternatively, the mutated version of ERCC2 may bind but not efficiently repair damaged DNA, thereby preventing repair by an alternative DNA repair pathway and leading to a dominantnegative phenotype, as has been described for mutants of the yeast ERCC2 homolog, Rad3 (28) . Further studies are necessary to explore the effects of ERCC2 loss on tumor growth, and the mechanism by which the identified ERCC2 mutations confer changes in tumor NER capacity.
One possible explanation for the findings observed in this study is that somatic ERCC2 mutation is associated with good prognosis small tumors. However, this is not supported by the survival data from the TCGA bladder cancer cohort, which excluded patients who received neoadjuvant chemotherapy. No difference in overall survival was observed based on somatic ERCC2 mutation status (Fig. S3) . In the extreme response cohort reported here, patients were generally noted to have obvious disease left behind after initial transurethral resection based on operative reports and imaging, making the findings unlikely related to complete transurethral resection. While these data should not yet be used to justify avoiding cisplatin-based treatment in ERCC2 WT patients, our findings raise the possibility that somatic ERCC2 mutation status may provide a genetic means to select patients most likely to benefit from cisplatin-based chemotherapy, while directing other patients towards alternative therapeutic approaches. Of note, our study focused specifically on somatic mutations that are exclusively in the tumor, and not germline single nucleotide polymorphisms in ERCC2 or other genes. Thus, this approach is distinct from genome-wide association studies that have examined germline ERCC1 or ERCC2 polymorphisms and their mixed impact on cisplatin sensitivity (29) . Broadly, these findings will require independent clinical validation in prospective trials to establish the clinical predictive power of somatic ERCC2 mutation status for cisplatin response.
It is possible that some nonresponding urothelial tumors will harbor somatic ERCC2 mutations in larger cohorts; if observed, examination of the post-chemotherapy resistant tumor would be critical to understand whether tumor heterogeneity played a role in resistance. The patients analyzed in this extreme phenotype analysis were treated with combination cisplatin-based chemotherapy regimens containing non-cisplatin agents; however, cisplatin was the only agent common to all regimens. Since half of patients with bladder cancer are not candidates for cisplatin-based chemotherapy due to preexisting comorbidities, less toxic carboplatin-based neoadjuvant therapies may warrant study for non-cisplatin eligible patients with ERCC2-mutant tumors To date, exceptional response genomic studies have informed genomic mechanisms of response to targeted therapies, such as response to everolimus in multiple disease contexts (30, 31) . However, published studies have been limited to individual case reports due to the rarity of such events with targeted therapies. This study represents a new approach for studying extraordinary responses to commonly used cytotoxic 
chemotherapies using a case-control design, which may be applied to other therapeutic settings in which a significant minority of patients achieve exceptional response (e.g. neoadjuvant chemotherapies in other clinical settings). Towards that end, a majority of responder cases in our cohort had no recurrent genomic determinant of cisplatin response. It is possible that alterations in DNA repair genes not readily detectable with WES (e.g. epigenetic, expression-based) may mediate cisplatin sensitivity in these cases.
In conclusion, this work provides new insights into the relationship between somatic 
METHODS
Patients and Samples
Whole Exome Sequencing and Statistical Analysis
DNA extraction and exome sequencing: Slides were cut from FFPE or frozen tissue blocks and examined by a board-certified pathologist to select high-density cancer foci and ensure high purity of cancer DNA. Biopsy cores were taken from the corresponding tissue block for DNA extraction. DNA was extracted using Qiagen's QIAamp DNA FFPE Tissue Kit Quantitation Reagent (Invitrogen). DNA was stored at -20 degrees Celsius.
Whole exome capture libraries were constructed from 100ng of DNA from tumor and normal tissue after sample shearing, end repair, and phosphorylation and ligation to barcoded sequencing adaptors. Ligated DNA was size selected for lengths between 200-350 bp and subjected to exonic hybrid capture using SureSelect v2 Exome bait (Agilent). The sample was multiplexed and sequenced using Illumina HiSeq technology for a mean target exome coverage of 121X for the tumors and 130X for germline samples. Four cases did not complete the exome sequencing process due to sequencing process failure. All BAM files generated for this study will be deposited in dbGap (submission in progress).
Sequence data processing: Exome sequence data processing and analysis were performed using pipelines at the Broad Institute. A BAM file aligned to the hg19 human All statistical calculations were performed using the R statistical package.
Mutation Validation
Orthogonal validation of selected mutations and short insertion/deletions (those presented in this manuscript, including ERCC2) was performed using the Fluidigm 
Cloning and Cell Lines
A site-directed PCR mutagenesis/BP recombination method(42) was used to generate WT and mutant ERCC2 open reading frames (ORFs). For each mutant, PCR products were generated such that fragments overlap at the region of the desired mutation. The fragments were then introduced into the pDONR vector through the BP reaction. The BP reaction mixture was transformed into E. coli and recombined to generate a pENTR vector. The pENTR vector was then used to perform the LR reaction to create an expression plasmid.
The expression plasmids harboring WT ERCC2, GFP (negative control), or mutant ERCC2s were expanded in E. coli TOP10 cells (Invitrogen) and purified using an anion exchange kit (Qiagen). Lentiviruses were propagated in 293T cells by cotransfection of the expression plasmid with plasmids encoding viral packaging and envelope proteins. 
Cisplatin Sensitivity Assays
Cells were transferred to 96-well plates at a density of 500 cells per well. Six hours later, cisplatin (Sigma) was serially diluted in media and added to the wells. After 96 hours, CellTiter-Glo reagent (Promega) was added to the wells and the plates were scanned using a luminescence microplate reader (BioTek). Survival at each cisplatin concentration was plotted as a percentage of the survival in cisplatin-free media. Each data point on the graph represents the average of three independent measurements, and the error bars represent the standard deviation. IC 50 concentrations were calculated using a four parameter sigmoidal model and plots were generated using Prism 
UV Clonogenic Survival Assays
Cells were seeded in 6-well plates (Nunc) at a density of 1500 cells per well. The following day, the cells were washed once with PBS and then exposed to increasing UV doses using a UV-B irradiator (Stratagene). Media was replaced and the cells were allowed to grow for nine days. On day 10, cells were fixed using a 1:5 acetic acid:methanol solution for 20 minutes at room temperature. Cells were then stained for 45 minutes using 1% crystal violet in methanol solution. Plates were rinsed vigorously with water, allowed to dry, and colonies were then manually counted. The number of colonies present at each UV dose was plotted as a ratio of the number of colonies 13 (26) 6 (24) The difference between the ERCC2-deficient cell line and the WT ERCC2 cell line was significant (P < 0.0001; ANOVA), whereas the difference between the ERCC2-deficient cell line and each of the ERCC2 mutant cell lines was not statistically significant (NS). 
